The SHARED, Project, Lung Cancer Screening for African American Men (AAM)

Status Active, not recruiting

Clinical Trial Summary

Clinical Trial Description

This study is a single-arm pre-test post-test design with a two-month follow-up assessment. The study aims to provide support to participants in quitting smoking and accessing lung cancer screening through the combination of education interventions and patient navigation (PN). After participant consent the study team will administer a series of surveys to collect the participant's contact information and complete the study's pretest measures. These include a demographic survey, smoking history, lung cancer knowledge, lung screening knowledge, intention to quit/screen, informed to decide, satisfaction survey, and decision conflict survey. The study also consists of three scheduled meetings with the PN lasting up to 60 minutes. The 1st session will be held between 7-14 days after consent. The 2nd session will be held 7-14 after the 1st session and the 3rd session will be held 42-49 days after the 1st session. Additional phone calls will last 10 minutes or less and be focused on specific questions generated by study participants. In the 1st session the PN will re-orient participant to the goals and objectives of the project and answer participant questions before starting the intervention. The 1st activity will be to show a 3 minute culturally tailored video that will explain the benefits of lung cancer screening for African American Males (AAM) using an internet-enabled device. After completion of the video, the PN will invite the participant to ask any questions that they have and the PN will offer clarifying information. The PN will review with the participant a culturally adapted shared decision-making tool. The participant will complete the posttest surveys as described abov. In the 2nd session the PN will determine the scheduling and completion of lung cancer screening and Illinois Tobacco Quit Line (ITQL) engagement. The participant will complete the LDCT screening, navigation needs, Quitline Engagement, and decision change surveys In the 3rd session the PN will determine scheduling, barriers and completion of lung cancer screening and Quitline engagement. The participant will complete LDCT screening check, and a Quitline engagement check ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05920850
Study type	Interventional
Source	University of Illinois at Chicago
Contact
Status	Active, not recruiting
Phase	N/A
Start date	July 14, 2023
Completion date	August 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02944903` - Audit of Lung Cancer Screening Practice in Chest Physicians: An Update	N/A
Recruiting	`NCT02292485` - PCORI-CER-1306-03385 Lung Cancer Screening Readiness Study
Active, not recruiting	`NCT05630950` - LDCT-SC-FI Low-dose CT Screening for Lung Cancer	N/A
Completed	`NCT03200236` - The Lung Screening, Tobacco and Health Project	Phase 3
Recruiting	`NCT03853967` - Lung Cancer Screening by Low Dose CT Scan in a French Department (DEP KP80)	N/A
Recruiting	`NCT05645731` - Lung Cancer Screening in Family Members and Peers of Lung Cancer Patients: a Prospective Cohort Study
Active, not recruiting	`NCT03069924` - Gain-framed Messages and NRT for Lung Cancer Screening Patients	Phase 2
Completed	`NCT02899754` - Lung Cancer Screening Decisions	N/A
Completed	`NCT03793894` - Inpatient Smokers and LDCT Screening Part 2	N/A
Active, not recruiting	`NCT04691297` - Digitally Enhanced Smoking Cessation for High Risk Smokers	N/A
Enrolling by invitation	`NCT05747443` - Multilevel Interventions to Increase Adherence to Lung Cancer Screening	N/A
Active, not recruiting	`NCT02914899` - Informing the Adaptation of a CHW Model to Facilitate Lung Cancer Screening for the Chinese Community	Early Phase 1
Recruiting	`NCT05195385` - Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study	N/A
Completed	`NCT03958253` - Lung Cancer Screening Protocol	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.